• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

喉原发性弥漫性大 B 细胞淋巴瘤。

Primary diffuse large B-cell lymphoma of the Larynx.

机构信息

Department of Otorhinolaryngology, Head and Neck Surgery, Juntendo University, Urayasu Hospital, 2-1-1 Tomioka, Urayasu-city, Chiba, Japan.

Department of Otorhinolaryngology, Head and Neck Surgery, Juntendo University, Urayasu Hospital, 2-1-1 Tomioka, Urayasu-city, Chiba, Japan.

出版信息

Auris Nasus Larynx. 2023 Aug;50(4):632-636. doi: 10.1016/j.anl.2022.07.001. Epub 2022 Jul 18.

DOI:10.1016/j.anl.2022.07.001
PMID:35863932
Abstract

The larynx is a rare site of extranodal non-Hodgkin lymphoma (NHL), accounting for less than 1% of all primary laryngeal neoplasms. We report a rare case of laryngeal diffuse large B-cell lymphoma (DLBCL) in an 85-year-old female patient, which was difficult to diagnose even after several biopsies from the primary laryngeal lesion, both under local and general anesthesia, and the diagnosis of DLBCL was obtained from the lymph node biopsy, which appeared in the proximity of the larynx 2 months after the first biopsy from the larynx. Since the diagnosis of laryngeal NHL is sometimes difficult when sufficient samples cannot be obtained, repeated biopsies may be required. Due to the small number of cases, there is no definite consensus regarding the best management of laryngeal NHL. Thus, a standard treatment option for DLBCL, such as 3 courses of R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine and prednisone) followed by Involved-field radiation therapy, or 6∼8 course of R-CHOP, are also applied for the treatment of laryngeal DLBCL. For this case, doxorubicin was not adopted and 8 courses of R-COP (rituximab + cyclophosphamide, vincristine and prednisone) at a decreased dose were chosen because of her age (85-year-old) and cardiac hypofunction.

摘要

喉是结外非霍奇金淋巴瘤(NHL)的罕见部位,占所有原发性喉肿瘤的不到 1%。我们报告了一例罕见的 85 岁女性喉弥漫性大 B 细胞淋巴瘤(DLBCL)病例,即使在局部和全身麻醉下对原发性喉病变进行了多次活检,也难以诊断,并且在第一次喉活检后 2 个月出现的靠近喉部的淋巴结活检中获得了 DLBCL 的诊断。由于当无法获得足够的样本时,喉 NHL 的诊断有时较为困难,因此可能需要重复进行活检。由于病例数量较少,对于喉 NHL 的最佳治疗方法尚无明确共识。因此,也适用于 DLBCL 的标准治疗选择,例如 3 个周期的 R-CHOP(利妥昔单抗+环磷酰胺、多柔比星、长春新碱和泼尼松),随后进行受累野放射治疗,或 6∼8 个周期的 R-CHOP。对于该病例,由于患者年龄(85 岁)和心脏功能低下,未采用多柔比星,选择了 8 个周期的 R-COP(利妥昔单抗+环磷酰胺、长春新碱和泼尼松),剂量降低。

相似文献

1
Primary diffuse large B-cell lymphoma of the Larynx.喉原发性弥漫性大 B 细胞淋巴瘤。
Auris Nasus Larynx. 2023 Aug;50(4):632-636. doi: 10.1016/j.anl.2022.07.001. Epub 2022 Jul 18.
2
Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.弥漫性大B细胞非霍奇金淋巴瘤的临床预后因素:一项回顾性研究。
J Egypt Natl Canc Inst. 2011 Mar;23(1):17-24. doi: 10.1016/j.jnci.2011.07.003. Epub 2011 Sep 8.
3
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.伊布替尼联合利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松(R-CHOP)治疗初治 CD20 阳性 B 细胞非霍奇金淋巴瘤患者:一项非随机、1b 期研究。
Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.
4
Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松化疗免疫治疗原发性难治性弥漫性大 B 细胞淋巴瘤的临床病理分析。
Cancer Med. 2021 Aug;10(15):5101-5109. doi: 10.1002/cam4.4062. Epub 2021 Jun 9.
5
3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis.R-THP-COP与R-CHOP方案治疗老年弥漫性大B细胞淋巴瘤的比较:单机构分析
Intern Med. 2017 Sep 15;56(18):2407-2413. doi: 10.2169/internalmedicine.8291-16. Epub 2017 Aug 21.
6
Extranodal site of diffuse large B-cell lymphoma and the risk of R-CHOP chemotherapy resistance and early relapse.结外弥漫性大 B 细胞淋巴瘤部位与 R-CHOP 化疗耐药和早期复发的风险。
Int J Clin Pract. 2020 Oct;74(10):e13594. doi: 10.1111/ijcp.13594. Epub 2020 Jul 14.
7
Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.真实世界环境中 B 细胞非霍奇金淋巴瘤患者的临床结局:来自血液肿瘤学拉丁美洲观察性注册研究的结果。
JCO Glob Oncol. 2022 Mar;8:e2100265. doi: 10.1200/GO.21.00265.
8
Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.复发弥漫性大 B 细胞淋巴瘤治疗相关直接费用。
Oncologist. 2019 Sep;24(9):1229-1236. doi: 10.1634/theoncologist.2018-0490. Epub 2019 Mar 8.
9
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.在预后良好的侵袭性 B 细胞淋巴瘤患者中,与六次利妥昔单抗联合使用相比,四个与六个周期的 CHOP 化疗(FLYER):一项随机、3 期、非劣效性试验。
Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9.
10
Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.在马拉维,利妥昔单抗治疗弥漫性大 B 细胞淋巴瘤患者的安全性和疗效:一项前瞻性、单臂、非随机 1/2 期临床试验。
Lancet Glob Health. 2021 Jul;9(7):e1008-e1016. doi: 10.1016/S2214-109X(21)00181-9. Epub 2021 May 19.